"Separating contenders from
pretenders in breast cancer"

-- ASCO Post

"Blazes a trail in breast cancer"

-- Nature Biotechnology

"A glimpse into the future of
phase II drug development?"

-- NEJM

I-SPY Email List Sign-up

Featured News

Upcoming FDA workshop: "Clinical Trials to Optimize Outcomes in Early Breast Cancer"

Announcement

September 14, 2018

I-SPY 2, an Innovative Clinical Trial Model that is Revolutionizing the Treatment of Early Stage, High-Risk Breast Cancer

Press Release

September 12, 2018

Advanced MRI methods tested in I-SPY 2 may improve monitoring and prediction of treatment response

Announcement

September 7, 2018

-- more news --

What is I-SPY?

The I-SPY series of trials are changing the way new treatments are developed for breast cancer, helping make available new, better and more personalized treatments, faster. At the heart of the I-SPY program is the ground-breaking I-SPY 2 platform trial for neoadjuvant treatment of locally advanced breast cancer.

1300

patients enrolled

16

agents completed
evaluation since 2010

3

agents received
accelerated approval

World-class science requires world-class scientists

Meet some of our team

Medical Oncologist

Swedish Cancer Institute

Assistant Professor

University of Colorodo Denver School of Medicine

Associate Professor of Medicine

University of Minnesota Medical School

W. Fraser Symmans

Director of Research Operations

MD Anderson Cancer Center

Don't miss a thing! Get I-SPY results, news and event information delivered right to your inbox.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

I-SPY is supported by:

I-SPY Sponsor:
‍

Quantum Leap Healthcare Collaborative